J L
Oct 23, 2014
Eli Lilly Says Canada Patent Ruling Violates NAFTA
Eli Lilly & Co. told an international trade body that Canada violated international law when it invalidated two of its key patents. The company said the invalidation by Canadian courts of patents for two Lilly drugs—Zyprexa, used in the treatment of schizophrenia; and Strattera, used to treat Attention Deficit Hyperactivity Disorder (ADHD)—is illegal and “constitutes an uncompensated expropriation,” according to the memorial it filed with the U.N. Commission on International Trade Law and the North American Free Trade Agreement.